Platelet Aggregation Inhibitors (Antiplatelet Drugs)

Subscribe to Selected New Research on Platelet Aggregation Inhibitors

1458 relevant articles (127 outcomes, 175 trials/studies) found for this Bio-Agent

Description: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Also Known As:

Antiplatelet Drugs; Blood Platelet Aggregation Inhibitors; Blood Platelet Antagonists; Blood Platelet Antiaggregants; Platelet Inhibitors; Agents, Antiplatelet; Aggregation Inhibitors, Platelet; Antagonists, Blood Platelet; Antagonists, Platelet; Antiaggregants, Blood Platelet; Drugs, Antiplatelet; Inhibitors, Platelet; Inhibitors, Platelet Aggregation; Antiaggregants, Platelet; Antiplatelet Agents; Platelet Antagonists; Platelet Antiaggregants

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 49

Therapeutic Uses: 203

Hematologic Agents: 1

Platelet Aggregation Inhibitors: 1458

Experts

1.	Duley, L: 5 articles (01/2007 - 01/2000)
2.	Knight, M: 4 articles (01/2007 - 01/2000)
3.	King, J F: 4 articles (01/2007 - 01/2000)
4.	Henderson-Smart, D J: 4 articles (01/2007 - 01/2000)
5.	Aronow, Wilbert S: 3 articles (02/2008 - 11/2003)
6.	Diener, Hans-Christoph: 3 articles (02/2006 - 08/2004)
7.	Billett, Henny H: 2 articles (05/2008 - 02/2006)
8.	Albers, Gregory W: 2 articles (01/2008 - 11/2007)
9.	Schwartz, Neil E: 2 articles (01/2008 - 11/2007)
10.	Mousa, Shaker A: 2 articles (06/2007 - 01/2004)

Related Diseases

1.	Stroke (Strokes) 09/01/2009 - "In the cases of distal embolic stroke, all three patients achieved good results following the use of antiplatelet agents. " 10/01/2003 - "Although antiplatelet agents have not proved to be beneficial in the primary prevention of stroke, they are recommended in patients with ICS in order to lower the risk of heart attack associated with this pathology. " 01/01/2008 - "Certain combination therapies appear to be more effective for secondary prevention of stroke or TIA than therapy with single antiplatelet agents. " 03/01/2004 - "OBJECTIVE: To provide an overview of the impact of ischemic stroke and the steps that can be taken to reduce its burden through greater awareness of the disease, improved diagnosis and better treatment, with emphasis on the use of antiplatelet agents. " 05/01/2004 - "Antiplatelet agents are effective for secondary prevention after ischemic stroke, although they do not always prevent recurrent events. " Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 01/01/1989 - "Data from meta-analysis and from more recent trials suggest that the clinical efficacy of antiplatelet drugs is likely related to their ability to interfere with thrombus formation. " 01/01/1992 - "Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. " 04/01/2009 - "The antiplatelet drugs work to decrease platelet aggregation and are especially effective in preventing and managing arterial thrombus. " 10/01/2005 - "As the activation of platelets during thrombus generation involves many complex and redundant pathways, simultaneous use of different antiplatelet drugs that are directed against different targets have been effective in reducing adverse clinical events. " 05/01/1989 - "Antiplatelet drugs utilized during the last four years were effective in preventing thrombosis at the operative site. " Order ALL the reference details at left...
3.	Myocardial Infarction 01/01/1989 - "Meta-analysis of several previous clinical trials, most of which were inconclusive, has recently ascertained the benefit of antiplatelet drugs in secondary prevention of myocardial infarction. " 03/01/1982 - "Clinical trials of antiplatelet agents in the secondary prevention of myocardial infarction and transient ischaemic attacks have so far been inconclusive. " 10/01/2007 - "Antiplatelet agents make a comeback in ST-elevation myocardial infarction." 03/01/2006 - "Ongoing research into various etiologies of perioperative myocardial infarction and other medications with potential efficacy in this setting, including the important antiplatelet agents, must also be considered in developing recommendations for widespread adoption of perioperative beta-blockade." 12/01/2005 - "We tried to determine the prognostic impact of triple (antiplatelet agents, statins and beta-blockers) and quadruple (the same+ACE inhibitors) combination therapy at hospital discharge after acute myocardial infarction. " Order ALL the reference details at left...
4.	Unstable Angina 08/01/2007 - "The newer antiplatelet drugs recommended in early intervention and discharge treatment strategies are underused across many segments of the unstable angina-NSTEMI population. " 11/01/1996 - "[Modern "antiplatelet agents" in unstable angina]" 12/09/1995 - "Thus the emphasis placed on measures capable of improving the anti-thrombotic risk in unstable angina by using new antiplatelet agents, or for certain patients at high risk of a major cardiac event, antithrombosis agents. " 10/01/1995 - "These new antiplatelet drugs are now being evaluated in clinical trials in patients undergoing balloon coronary angioplasty, in whom fewer ischemic events occur when the receptor blocker is used intravenously than with standard therapy, and in patients with stable and unstable angina. " 08/01/2001 - "These data suggest that early angioplasty of unstable angina patients is safe and may be cost-effective, even in the absence of stenting and potent antiplatelet agents. " Order ALL the reference details at left...
5.	Cardiovascular Diseases (Cardiovascular Disease) 09/25/1990 - "The protective effects of platelet inhibitors in primary and particularly in secondary prevention of cardiovascular diseases have been documented in numerous studies. " 01/01/2006 - "This article reviews the centrality of the platelet in atherothrombosis and briefly looks at the efficacy of antiplatelet agents in preventing and treating cardiovascular disease." 09/01/1999 - "Since platelet inhibitors for long-term prophylaxis of cardiovascular diseases are still in clinical trials there are many unanswered questions about long-term effects both positive and negative. " 03/01/2009 - "Platelets are a pre-requisite for the formation of arterial thrombi and, as a consequence, novel antiplatelet agents are sought to meet the significant clinical need for a potent, safe, and orally available therapy for the management of cardiovascular disease. " 02/01/2009 - "Thus, for the prevention of cardiovascular diseases, there is still a clinical need for antiplatelet drugs with higher antithrombotic efficacy but with safety profiles that allow for a preventive long-term administration. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Anticoagulants
3.	Dipyridamole (Persantine)
4.	clopidogrel (Plavix)
5.	Warfarin (Coumadin)
6.	Ticlopidine (Ticlid)
7.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
8.	Glycoproteins (Glycoprotein)
9.	Heparin (Liquaemin)
10.	Fibrinolytic Agents (Antithrombotic Agents)

Related Therapies and Procedures

1.	Stents
2.	Transplants (Transplant)
3.	Carotid Endarterectomy
4.	Angioplasty (Angioplasties)
5.	Plasmapheresis

Best Treatments:
Research Summary Report
on Stroke

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2274 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>